SCHEMBL14855144

SCHEMBL14855144

Nc1ccc(OCc2ccc(Cl)cc2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 8/20 0.49
MAOB P27338 5/20 0.49
MRGPRX4 Q96LA9 2/20 0.47
MPO P05164 1/20 0.44
SLC6A4 P31645 2/20 0.43
IDO1 P14902 1/20 0.43
AGXT P21549 1/20 0.43
MAOA P21397 1/20 0.43
TACR2 P21452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319489 0.87 MAOB (0.59) CCR5MAOBSLC6A4IDO1AGXT
SCHEMBL14854821 0.83 MRGPRX4 (0.55) CCR5MAOBMRGPRX4MPOSLC6A4
SCHEMBL371725 0.83 MAOB (0.53) MAOBMRGPRX4MAOA
SCHEMBL14855393 0.83 MRGPRX4 (0.56) MAOBMRGPRX4MPOSLC6A4IDO1
Hydrochloric Acid SCHEMBL11418706 0.82 MAOB (0.51) MAOBMRGPRX4MAOA
SCHEMBL20607894 0.81 NPC1 (0.51) MAOBIDO1AGXT
SCHEMBL30792359 0.81 CCR5 (0.46) CCR5MAOBMRGPRX4MPOSLC6A4
SCHEMBL3571738 0.80 SYK (0.55) CCR5MAOBMRGPRX4MPOSLC6A4
SCHEMBL5571351 0.78 MAOB (0.53) MAOBMRGPRX4MAOA
SCHEMBL30385339 0.78 PTPRZ1 (0.55) MAOBMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-9676724-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
WO-2011153942-A1 CYANOQUINOLINE DERIVATIVES 天津和美生物技术有限公司 (CN) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246443-B2 Cyanoquinoline derivatives CBR3, CYP3A4, CDK1 CCR5 732/4885MAOB 1410/4885MRGPRX4 1090/4885
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 CCR5 732/4885MAOB 1410/4885MRGPRX4 1090/4885
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 CCR5 732/4885MAOB 1410/4885MRGPRX4 1090/4885
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 CCR5 732/4885MAOB 1410/4885MRGPRX4 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.